Clinical Trial

Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 17, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This trial aims to assess efficacy and safety of durvalumab combined with chemoradiotherapy for limited stage small cell lung cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-04-14.
Trial Details
NCT Number NCT06371482
Lead Sponsor Hebei Medical University Fourth Hospital
Conditions SCLC, Limited Stage
Enrollment 58 participants
Start Date 2023-06-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-06-17